Trial intelligence / Profile preview

Biweekly cetuximab plus FOLFOX-4 in first-line KRAS wild-type metastatic colorectal cancer

2008-006909-16Phase 2Active

Sponsor: ACROSS:AssociaciÃ³ Catalana per a la Recerca OncolÃ²gica i les seves implicacions sanitÃ ries i Socials
Start: Feb 2009
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by ACROSS:AssociaciÃ³ Catalana per a la Recerca OncolÃ²gica i les seves implicacions sanitÃ ries i Socials. Primary endpoint: Confirmed objective response rate. Started Feb 2009; status: active.

Drugs

cetuximaboxaliplatinfluorouracilfolinic acid

Conditions

colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)

Beyond the preview

Go deeper on 2008-006909-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-006909-16.